The Impact of Ketogenic Nutrition on Obesity and Metabolic Health: Mechanisms and Clinical Implications.

INTRODUCTION

According to the World Health Organization, the incidence of obesity worldwide has nearly tripled since 1975. Lifestyle changes, including the nutritional shift to highly processed foods rich in saturated fats and carbohydrates, 1 increased sedentary lifestyle and urbanization, 2 reduced physical activity, 2 , 3 poor sleep habits, 4 and increased stress, 5 are all predisposing factors for weight gain. Globally, with the exception of some sub-Saharan African regions and Asian regions, the incidence of obesity is higher than the incidence of underweight. 6

Obesity is defined as excessive fat accumulation and is a more serious condition than overweight. The most commonly used index for the classification of overweight/obesity in adults is body mass index (BMI; kg/m 2 )—the ratio of body mass to the square of body height. A BMI in the 25–30 kg/m 2 range corresponds to a status of overweight, while a BMI >30 kg/m 2 defines obesity and a BMI >35 kg/m 2 is indicative of morbid obesity. 7 BMI does not univocally inform on the ratio between fat and lean mass, a measure that can be obtained by dual-energy X-ray absorptiometry (DXA). Yet, BMI is still strongly correlated to DXA and is an acceptable predictor of obesity-related morbidities at the population level. 8 Obesity, in turn, is a risk factor for coronary heart disease or stroke, musculoskeletal diseases such as osteoarthritis, type 2 diabetes, hypertension, gallbladder disease, dyslipidemia, sleep apnea and breathing problems, 9–11 reduced fertility, 12 , 13 and multiple types of cancers including endometrial, breast, ovarian, prostate, liver, gallbladder, kidney, and colon cancer. 14–16 Many studies also suggest that people with obesity are more prone to mental illness conditions, such as clinical depression or anxiety. 17–19 Because of these detrimental effects on health, weight-loss strategies in the population with obesity can be viewed as a preventive approach to alleviate the incidence of obesity-associated disorders.

In recent years, the ketogenic diet (KD), which aims at providing a normal-protein, high-fat, and low-carbohydrate (<50 g/d) intake, has been proposed as a weight-loss strategy. A KD, which is highly restricted in carbohydrates, was used from the 18th century as a remedy for diabetes. 20 Likewise, the KD has been used for over a century as an effective anti-epileptic treatment 21 and is still used today to treat pharmacologically refractory forms of epilepsy, 22 , 23 or rare genetic conditions such as glucose transporter 1 (GLUT1) deficiency syndromes. 24 In these specific situations, there are no alternatives to the KD, and patients must follow this diet continuously.

In weight-loss approaches, the usefulness of a KD has yet to be firmly established, and discordant studies provide different results on the matter, not least because of the multiple experimental protocols applied, the intrinsic variability in the KD administered in each study, and the occurrence of potential side effects. Here, several open questions related to the use of a KD to attain weight loss are discussed, the first of which is whether fatty acids can almost completely substitute carbohydrates as body fuel. Then, the evidence supporting the association between the obese state and multiple morbidities in humans is discussed, and finally focusing on the outcomes of studies investigating the use of a KD to curb obesity, with particular attention to the experimental protocols and their duration, KD composition, and the quality of fats, which are all factors affecting study outcomes.

METHODOLOGY OF THE LITERATURE SEARCH

Medline and Scopus databases were searched for original articles and reviews using the following key words and terms, used alone or in combination: anti-cancer therapy, ATP, cancer, carbohydrates, cardiovascular diseases, diabetes, endocrine diseases, energy production, inflammation, intermittent fasting, KD, ketone bodies, ketolysis, ketogenesis, lipids, obesity, musculoskeletal diseases, PCOS, proteins, supplementation, therapeutic potential. Clinical trials were searched in the National Institutes of Health (NIH) register (clinicaltrials.gov) and in the European Council EU Clinical Trials Register ( https://www.clinicaltrialsregister.eu ).

COULD FAT BE THE MACRONUTRIENT OF CHOICE TO PRODUCE ENERGY AND CURB OBESITY?

The optimal dietary macronutrient balance has been a longstanding topic of discussion, with current guidelines suggesting that adults derive 55%–70% of energy from carbohydrates, 15%–20% from fats, and 7%–20% from proteins. 25 Poor nutritional education often leads people to rely on highly processed foods to ensure a supply of calories and a quick feeling of satiety. However, these highly processed foods, such as salty snacks and sugar-sweetened beverages, are characterized by a high glycemic index (GI) and deliver quickly absorbed nutrients that cause dopamine-triggered satisfaction and contribute to metabolic health issues and addictive eating behaviors. 26 , 27

Fats are highly energy-dense, containing 9.0 kcal/g, more than double the energy provided by carbohydrates and proteins, which yield 4.0 kcal/g. This makes fat an efficient energy source providing a sustained release of energy that supports longer-lasting satiety compared with more rapidly metabolized carbohydrates. This satiety effect can aid weight management and in supporting calorie control. However, the role of fat in weight management is strongly related to the ratio between fat and carbohydrate intake, and ketone body production conditions. Physiologically, carbohydrate intake inhibits fat utilization. An excess of carbohydrates induces hyperinsulinemia and serves as lipogenic substrate, promoting fat accumulation and obesity, lending credibility to the proposed carbohydrate-insulin model (CIM) as a theoretical model explaining the development of obesity. 28 Hence, shifting the metabolism into fat oxidation and fatty acid–derived ketone bodies is possible only after dietary carbohydrate deprivation, which causes nutritional ketosis (ketone bodies >0.5 mmol/L) with a concomitant increase in dietary fat consumption over a period of several weeks. 29–31 In these circumstances, ketone bodies replace most of the glucose required by the brain, while liver gluconeogenesis provides the limited amount of energy needed by glucose-dependent tissues such as red blood cells, retina, and the renal medulla. 32

During intestinal transit, fats tend to delay gastric emptying, thereby slowing down the digestion and absorption of carbohydrates. This means that a high-fat meal will have a lower glycemic effect than a low-fat meal, even if both contain the same amount and type of carbohydrates. A study by Lilly et al 33 found that supplementation with peanut butter reduced blood glucose spikes and the overall glycemic response to a high-GI meal, potentially representing a beneficial approach to prevent blood glucose spikes.

The type of fat consumed plays a significant role in determining its impact on metabolic health, obesity, and cardiovascular risks. The debate often centers around the effects of different types of fats, notably trans -fats (also known as trans -unsaturated fats) and cis -fats (commonly found in most naturally occurring unsaturated fats). 34 , 35 Understanding the distinctions between these types of fats and their metabolic effects is crucial to evaluating whether fat can indeed serve as a beneficial macronutrient for energy homeostasis and obesity management ( Table 1 ). 36–45

Additionally, fats influence the body’s hormonal response, including the release of hormones such as ghrelin, often called the “hunger hormone,” and leptin, which helps regulate appetite and energy balance. Diets higher in healthy fats can modulate these hormones in a way that promotes satiety and reduces caloric intake, potentially making fat an effective macronutrient for managing obesity. 46 , 47 In conclusion, while fat can indeed be a valuable macronutrient for energy production and weight management, the type of fat is crucial in determining its effects on health and obesity.

KETONE BODIES ARE A LAST-RESORT FUEL

Lipid metabolism begins with the hydrolysis of triglycerides into free fatty acids and glycerol ( Figure 1 ). Fatty acids undergo β-oxidation to form acetyl coenzyme A (acetyl-CoA), or acetyl-CoA and propionyl-CoA for fatty acids with an odd number of carbon atoms. 48 When excessive acetyl-CoA is produced, overloading the Krebs cycle, acetyl-CoA is shunted to ketogenesis. The 3 main circulating ketone bodies are d -3-hydroxybutyrate—also named β-hydroxybutyrate (BHB), acetoacetate (AcAc), and acetone (Ac). They are continuously produced in small amounts, along with glycolysis, reaching physiological plasma concentrations of 0.05–0.25 mmol/L in a circadian manner. During ketosis, ketone body production is augmented in parallel with decreased carbohydrate availability, making ketones the main metabolic fuel. In pathological conditions, such as diabetic ketoacidosis, ketone body levels exceeding 15 mmol/L may become life-threatening. 49 , 50

METABOLIC CONTROL OF KETONE BODY LEVELS

The balance between basal metabolism, physical activity, and food intake contributes to the long-term determination of body weight. In accordance with the Energy Balance Model (EBM), a negative energy balance causes weight loss, while a positive energy balance leads to storage of the excessive energy accumulation, mainly in the adipose tissue, promoting obesity. 51 Stored fat may, however, be mobilized to induce a state of ketosis during starvation, exercise, or with a KD. Under these different conditions, in which the common thread is an initial depletion of the glucose and glycogen stores, fatty acids are mobilized from adipose tissue, which is constituted by more than 80% of fatty acids, and transported to the liver for conversion into ketone bodies. However, induction of ketogenesis has its limitations, and modulation of ketone levels can be very risky to health if not handled properly. The optimal flow of fuel for the brain and muscles depends on the level of serum ketone bodies, more specifically BHB ( Figure 2 ).

Prolonged Fasting and Starvation

Starvation is defined as a prolonged fasting (>7 days) and can theoretically be prolonged for weeks (or even months) in humans. 52 At the beginning of a starvation period, glucose is obtained from the breakdown of glycogen stores. 53 Once glycogen stores are depleted, usually after 2–3 days of fasting, fats stored in adipose tissues are hydrolyzed into free fatty acids and glycerol, with glycerol being a gluconeogenic precursor, and free fatty acids substrates for β-oxidation and ketogenesis.

Upon prolonged fasting, protein degradation is also initiated. This phase is considered as the beginning of starvation. Protein degradation, mainly from skeletal muscle tissues, also provides precursors for ketone body synthesis, which can reach concentrations of approximately 8 mmol/L. Excessive protein deprivation will affect the functioning of vital organs, which is a life-threatening condition. Obviously, a weight-loss program must not be pushed to such limits.

Physical Activity

Skeletal muscle accounts for the largest fraction of total ketone body utilization at rest. 54 Exercise increases the absolute rate of skeletal muscle ketone uptake and oxidation, 55 similarly to a short-term starvation or ketone body infusion. 56 Ketone body catabolism in human skeletal muscle increases up to 5 times during exercise. 54 Immediately after the start of exercise, a decrease in ketone bodies—mainly BHB—is observed, with a concomitant increase in skeletal muscle ketone uptake and oxidation and an elevated ketone body metabolic clearance rate (MCR). The MCR measures the ability of tissues to remove ketones from the blood. During exercise, the MCR represents an index of the ability of exercise to stimulate the ability of contracting muscles to uptake and catabolize ketone bodies. 54 Under a low ketonemia (<1 mmol/L) resulting from an overnight fast, resting MCR is up to 4 times greater than during prolonged fasting (>72 hours). Low- to moderate-intensity endurance exercise training after an overnight fast leads to an increase in MCR by 50%–70%. This shows that working muscles have an increased ability to extract ketones from blood compared with the resting state. 54 However, the exercise-induced increase in ketone body uptake reaches a plateau when plasma ketone body concentrations exceed approximately 3–4 mmol/L, indicating that saturation of ketone uptake has been achieved. 56 Two-hour treadmill exercise at 50% of maximum oxygen uptake (VO 2max ) was shown to stimulate whole-body absorption of ketones along with induced hyperketonemia (∼5.5–6 mmol/L) by exogenously delivered ketone bodies. Importantly, this was only observed in overnight-fasted subjects, but not in those who achieved similar levels of hyperketonemia by short-term fasting. 57 The oxidation rate of the ketone body was found to increase by approximately 3- to 5-fold during 30 minutes of cycling at 60% VO 2max in fasting subjects. Furthermore, it was observed that the ketone oxidation rate increased from approximately 0.44 mmol/L per minute at rest to approximately 2.1 mmol/L per minute (or ∼13 g/h) in the early stages of exercise, but then decreased to approximately 1.4 mmol/L per minute (or ∼9 g/h). 58 Physical exercise itself has a short-term effect on increasing ketone levels. Together with a proper nutrition regimen, physical exercise accelerates weight reduction and may have a positive effect on morbidities associated with excessive body weight.

SUPPLEMENTATION OF KETONE BODIES OR KETONE BODY PRECURSORS

As the adaptation to the KD, also termed “keto-induction,” may be unpractical and unpalatable, other methods to induce ketosis have been introduced. Leucine supplementation was suggested to be beneficial in increasing ketone bodies (especially BHB) as leucine, together with lysine, is the most ketogenic amino acid. Leucine supplementation was studied in 30% calorie-restricted rats and, at 6 weeks of administration, increased consumption of leucine resulted in retained lean body mass and protein mass while improving protein anabolism. Leucine supplementation also increased the amount of leptin and ketone bodies, but no changes in cholesterol or triglyceride levels were observed. 59 One study in humans has shown that butyric acid is even more ketogenic than either leucine or 8-carbon monoglycerides. 60

Under real-life nutritional conditions to reach high BHB levels, great emphasis is placed on the supplementation of ketogenic medium-chain fatty acids (MCFAs). 61 MCFAs encompass 6–12 carbon chains, including caproic (C6), caprilic (C8), capric (C10), and lauric (C12) acid. MCFAs induce both ketonemia and, in the long-term, ketogenesis, increasing BHB in a linear, dose-dependent manner. 61 Ketosis is induced relatively quickly after MCFA ingestion, as MCFAs are absorbed directly into the liver's portal vein instead of transiting via the lymphatic system. As a consequence, MCFAs are swiftly converted to ketones after β-oxidation in the liver. 62

An alternative way to promote ketonemia is the use of exogenous ketone esters and ketone salts in the form of “ketone drinks.” Dietary ketone salts are usually a racemic mixture of the BHB stereoisomers R-BHB and S-BHB, 63 but also ketone esters or the ketone bodies precursor 1,3-butandiol. 64 Soto-Mota et al 65 analyzed the safety and tolerability of sustained (28 days) exogenous ketosis developed by using ketone drinks, providing information that such supplementation is safe for healthy adults with no changes in kidney function, blood glucose, triglycerides, cholesterol, or electrolytes. In addition, body weight and composition also remained the same. In this study, participants consumed a normal, balanced diet, with the exception of 3 participating athletes who were also on a KD. Another study reported that, although exogenous ketones increase serum BHB (up to 6 mmol/L), they are not ketogenic and may, in fact, inhibit the production of endogenous ketones from endogenous lipid depots. In other words, exogenous ketones directly promote ketonemia but do not stimulate ketone body biosynthesis in the liver. 61 In a 14-day study, supplementation of a ketone monoester (KME) drink containing BHB prior to each meal to obese participants lowered postprandial and 24-hour average blood glucose levels, and increased brachial artery flow-mediated dilation—supporting a vascular benefit of the KME. However, the short study duration did not allow drawing conclusions on a potential effect on weight loss. 66 Exogenously provided ketones may not directly induce weight loss, but they reportedly improved energy yield during exercise (eg, in healthy male athletes exercising for 1 hour on a bike at 75% of maximum exercise intensity, BHB levels increased from 0.1 to 3.4 mmol/L after consuming a ketone drink) and improved mental health. 67 This study suggests that ketone body supplementation, while not curative against obesity, may serve as a preventive and supportive factor in obesity treatment. 67

KETOGENIC DIETARY STRATEGIES

A high-fat, low-carbohydrate diet is the most efficient source of ketone bodies. Research on a low-carbohydrate diet as a weight-loss approach dates back to the 1970s. 68 The reduction in quickly digestible starches and sugars has been reported as a key factor in reducing the risk of obesity, diabetes, and cardiovascular disorders. 69 Studies have shown that a ketogenic dietary approach is superior to others in terms of rapid weight loss in the first 6–12 months. A first randomized controlled trial aiming at evaluating the efficacy of a low-carbohydrate, high-protein, high-fat diet (of the Atkins diet type) in comparison to a classical diet showed significant weight loss at 3 and 6 months, but no significant difference at 12 months. 70 The 2-year Dietary Intervention Randomized Controlled Trial (DIRECT) compared (1) a low-fat diet, restricted in calories; (2) a Mediterranean diet, restricted in calories; and (3) a low-carbohydrate diet, nonrestricted in calories. Among the 3 diets, and at a 2-year follow-up, the greater weight loss was observed in the low-carbohydrate diet, with a parallel favorable affect in lipid profiles. 71 In a 20-week study, 164 participants were randomly assigned a low-carbohydrate (20%), medium-carbohydrate (40%), or high-carbohydrate (60%) diet. In those who followed the low-carbohydrate diet, energy expenditure increased by approximately 200–250 kcal per day, 72 suggesting that carbohydrate restriction may be more effective than fat restriction in treating obesity and maintaining weight loss. Moreover, a study of 262 adults with type 2 diabetes who followed a 2-year low-carbohydrate diet showed an average weight loss of 11.9 kg, as well as a reduction of glycosylated hemoglobin (HbA1c) by 1.0%. 73 Another study of 316 children and adults with type 1 diabetes following a very-low-carbohydrate diet documented a mean HbA1c of 5.7%, low rates of hypoglycemia and ketoacidosis, and also improved cardiovascular disease risk profile. 74 To date, several different varieties of low-carbohydrate diets have been proposed, such as the South Beach diet, Zone diet, Atkins diet, and KD; however, only the KD induces a sustained shift towards biosynthesis and use of ketone bodies.

Ketogenic Diet: The Most Efficient Nutritional Pattern to Induce Ketone Body Production

Currently, one of the most investigated eating patterns that substantially alter metabolic energy production is the KD, which is based on a minimal amount of carbohydrates (<5% in calories) and nutritionally optimal amount of protein (10%–20% of calories), with a simultaneous high supply of fats (∼80–90% of calories). Limiting carbohydrates to less than 50 g per day causes a loss of glycogen and the hepatic production of ketone bodies from fat stored in adipose tissue. Dietary ketosis, defined by BHB levels greater than 0.5 mmol/L in blood or urine, is induced in the first 2–5 days after starting the diet. 60 This “initiation phase” can cause side effects such as constipation, halitosis, muscle spasms, diarrhea, skin rash, and more. Such symptoms, however, resolve within a few weeks of following the KD.

In addition to the standard KD, a number of different variants have been proposed due to several ways of inducing a state of ketosis. This includes the very-low-carbohydrate KD (VLCKD), medium-chain-triglyceride KD (MCTKD), the calorie-restricted KD (CRKD), the cyclic KD, the targeted KD, and the high-protein KD. 75–79 Because of this variability, it must be underlined that a standardized and universal formulation of the KD does not exist (as it also does not exist for any other kind of diet). The compositions of the main types of KD are summarized in Table 2 . 76 , 80–82

Gibson and colleagues 83 compared, in a systematic review, very-low-energy diets (VLEDs) and KDs. The VLED users were found to be less hungry and more satiated, and KD users reported a decreased desire to eat. These results were relevant because of the typical increase in appetite in obese people. Overall, these studies suggest that ketosis appears to be effective in suppressing the appetite. While several studies show that a high-fat, low-carbohydrate diet is beneficial in losing weight and improving overall body parameters in the short–medium term, 84 the most clinically relevant evidence must come from long-term efficacy. In this respect, a prospective clinical trial demonstrated persistent weight loss after 2 years on a low-carbohydrate diet. 85 The same study, however, showed comparably persistent body-weight loss with a low-fat diet, underscoring the notion that the primary driver of weight loss is more attributable to the balance between caloric intake and caloric expenditure, supporting the EBM model, rather than dietary macronutrient composition. Both diets were, however, not associated with significant improvements in endothelial vascular function as measured by flow-mediated vasodilation. 86

ALTERNATIVE DIETARY STRATEGIES TO ATTAIN ENHANCED KETONE BODY PRODUCTION—INTERMITTENT FASTING

Intermittent fasting is among the eating patterns that has recently received much attention for supporting weight loss while increasing the concentration of ketone bodies. 87 During circadian fasting (ie, overnight), serum ketone levels increase naturally, but on a daily basis their concentration can be modulated through dietary routine. Intermittent fasting is a time-limited feeding period, usually based on the “16/8 system,” consisting of 16 hours of fasting and an 8-hour “eating window.” Intermittent fasting is typically associated with the consumption of a balanced diet with normal daily calorie intake in healthy individuals. Intermittent fasting also includes “every other day fasting,” in which fasting is extended to a 24-hour duration every second day. 88

Intermittent fasting associated with energy restriction caused weight loss in obese people. 89 This finding supported previous studies, 90 , 91 in which intermittent fasting was even more beneficial than continued energy restriction in promoting insulin sensitivity. Interestingly, lean mass and resting energy expenditure were found to be the same regardless of continued energy restriction or the use of intermittent fasting. 89 In a pilot study, the use of 2-day intermittent fasting resulted in a similar improvement in glycemic control in individuals with type 2 diabetes as compared with continued energy restriction, providing an alternative treatment strategy. 92

There are 3 main theories for reducing metabolic and cardiovascular risk factors by intermittent fasting: the oxidative stress hypothesis, the circadian rhythm, and the ketogenic state. The oxidative stress hypothesis suggests that mitochondria produce fewer free radicals due to reduced energy intake, resulting in reduced inflammation. The circadian rhythm approach evolved with regard to timing of eating patterns. Properly planned meal times can allow for optimization of the peripheral clocks of the liver, adipose tissue, and skeletal tissue. Physical, mental, and behavioral changes are influenced by factors such as increases and decreases in blood pressure and secretion of hormones depending on the time of day and exposure to light. Hence, circadian regulation appears to be at the core of all biological processes in the body. Therefore, daily misalignment leads to an increased risk of chronic diseases, as proven by a higher rate of cardiovascular disease in shift workers. Some studies suggest that ketone bodies can affect the circadian rhythm by modulating the expression of clock genes. 93 , 94

Intermittent fasting and the KD share some metabolic similarities, as these 2 eating patterns seem to have the most promising effects in terms of increasing ketone levels and reducing body fat. However, in a case report, prolonged fasting after a KD resulted in “starvation ketoacidosis,” which is a life-threatening condition. 95 In the implementation of a KD to maintain ketosis at an optimal and safe level, fasting and eating times must be carefully planned. This requires support from experienced physicians and/or nutritionists and good compliance by the patient. Hence, as with any restrictive diet, intermittent fasting with an associated KD should not be used by pregnant women, children, and those engaged in heavy physical labor.

THE ROLE OF KETONE BODIES IN OBESITY AND OBESITY-RELATED DISEASES

Research into the antidiabetic potential of the KD dates back to the 17th century, 20 and was then introduced by pediatrician Hugh Conklin in the treatment of drug-resistant epilepsy in the 1920s. 96 , 97 This diet has proven its usefulness in achieving a lasting seizure-free condition, with a return to the traditional diet resulting in relapse. 98 Recent studies show that the KD can successfully reverse metabolic abnormalities in diabetic patients by improving blood glucose levels while reducing insulin requirements, and significantly participate in the attenuation of inflammatory response. 99 In addition, the potential of the use of a KD in the treatment of hyperlipidemic patients has also been hypothesized. 100 The most important molecular effects exerted by ketone bodies are summarized in Figure 3 .

Obesity is associated with the release of proinflammatory mediators such as interleukins or tumor necrosis factor-α, but also reduced production of anti-inflammatory adiponectin. In this respect, the KD has been administered in patients with obesity and as obesity-related conditions, such as chronic kidney disease, cancer, or cardiovascular diseases, which are also characterized by a proinflammatory environment; several clinical trials have explored the usefulness of the KD in these pathologies.

THE EFFECT OF THE KD ON METABOLIC DISORDERS

Cardiovascular Diseases

The accumulation of visceral fat is recognized as a major cardiometabolic risk factor promoting the production of proinflammatory cytokines and adipokines with cardio-depressant and pro-atherosclerotic properties. 101–103 Overweight is also associated with hypertension, the dominant cause of heart failure. 104 , 105 A 5% weight gain leads to a 20%–30% increase in the incidence of hypertension. 106 In physiological conditions, the largest consumer of energy (∼400 kcal/kg/d) of all tissues is the adult human heart, which uses all energy sources, with particular emphasis on fatty acids (both in the nonesterified and esterified form) and carbohydrates. 107 Physiologically, the heart is a “metabolic omnivore” as it has the metabolic flexibility to switch from 1 substrate to another, depending on its availability. 108 Thus, cardiomyocytes use ketone bodies in proportion to their supply, making the heart muscle the largest consumer of ketone bodies per unit mass. 109 Such metabolic flexibility is lost in pathological conditions and, along with altered substrate utilization, is correlated with changes in mechanical function. In early stages of heart disease, the use of substrates shifts from fatty acids to glucose, leading to a reduction in oxidative metabolism. Such reprogramming underlies myocardial energy starvation, contributing to the pathogenesis of heart failure. Interestingly, while fatty acid oxidation is reduced, a failing heart appears to reprogram the metabolism to rely even more on ketone bodies as an energy supply. 110

Studies have shown that circulating ketone bodies and their use in the myocardium are increased in both heart failure with a reduced ejection fraction and a conserved ejection fraction. 111 As signaling molecules, ketone bodies can suppress systemic inflammation and cardiac inflammation, suggesting that a deliberate increase in circulating ketone bodies may be beneficial in the event of heart failure. 112 , 113 This can be achieved by ingesting ketone body precursors such as 1,3-butanediol or medium-chain triglycerides (MCTs) as well as ketone salts and ketone esters. A study by Tzenios et al 114 found that, in overweight patients, body composition and cardiometabolic markers improved after 140 days on a VLCKD.

Diabetes

Obesity increases the likelihood of type 2 diabetes or insulin resistance. 115 One of the most serious and even life-threatening complications of diabetes is diabetic ketoacidosis, which appears in conjunction with hyperglycemia when glucose uptake by tissues is failing because of a lack of insulin (in type 1 diabetes) or insulin resistance. When tissues cannot internalize glucose, the body response consists of switching to hepatic ketone body synthesis as an alternative energy source. When circulating ketone bodies become excessive, blood becomes more acidic (venous blood pH <7.3), leading to diabetic ketoacidosis. To avoid this, in patients with diabetes it is important to measure not only blood sugar levels but also ketones. 116 , 117 The main metabolic parameters of a KD and diabetic ketoacidosis are shown in Table 3 .

Musculoskeletal Diseases, Osteoarthritis

The impact of obesity and metabolic syndrome on the musculoskeletal system (muscles, bones, and joints) is pervasive and ranges from obesity-linked sarcopenia (where individuals gain fat mass but lose lean muscle mass) to diabetic osteoporosis and arthritis. 118 , 119 All of these disturbances result from degenerative and systemic inflammatory conditions that accompany obesity, 120 including osteoarthritis (OA). Osteoarthritis is a multi-tissue disease of joints, characterized by cartilage degradation, subchondral bone sclerotization, ectopic bone outgrowths on joints (osteophytes), and moderate synovial membrane inflammation. The main risk factors for OA are aging and trauma, but, as mentioned previously, an additional important and compounding risk factor is obesity. First, excessive body weight places extra pressure on lower body joints—every 5 kg of weight gain confers a 36% increase in the risk of the knee osteoarthritis 121 and an 11% increased risk of hip osteoarthritis. 122 Second, a pro-inflammatory adipokine profile linked to dyslipidemia and abnormal fat tissue metabolism worsens OA progression. 123 , 124 Third, systemic low-grade inflammation contributes to cartilage degeneration and synovial tissue inflammation. 125

Currently, the global prevalence of osteoarthritis is escalating due to both the aging population and the epidemic of obesity. 126 Based on the etiology of the disease, the body-weight factor seems to be of importance during OA treatment as obesity causes mechanical stress and metabolic inflammation resulting in accelerated cartilage damage and, ultimately, premature and severe OA. Intermittent fasting should be considered in weight-loss programs and its benefits are proven for the nonsurgical management of OA. 127 , 128 The benefits of fasting in OA can be explained by changes in advanced glycation end-products (AGEs) and their receptors (RAGEs), both identified as important elements in the pathology of OA. In a cohort of 37 patients with OA who underwent fasting for 8 days, a significant, but non-sustained, reduction in RAGE levels in serum but not of AGEs was found; however, no correlation with improvement in clinical endpoints of OA was found. 129 Low-carbohydrate diets have been reported to provide relief from osteoarthritis of the knee, 130 but it is unknown whether a high-fat and low-carbohydrate diet can achieve the same result. Initial experiments by Masino and Ruskin 132 demonstrated that such a dietary regimen, approximating a KD, can reduce inflammation and thus pain associated with inflammation. 131 However, further investigations will be necessary to determine whether circulating ketone bodies contribute to OA symptom improvement after intermittent fasting.

In connection with this open question, Felson et al 133 analyzed whether fatty acid levels affected the development of OA. It is known that saturated and n–6 fatty acids increase inflammation, whereas n–3 fatty acids reduce inflammation. Despite previously described effects on systemic inflammation, it was found that blood levels of fatty acids were not associated with risk of later knee OA or other OA outcomes. These studies, focused on the role of a KD in rheumatoid arthritis (RA), revealed its low efficacy. 134 , 135 It was found that fasting, but not a KD, significantly decreased serum interleukin-6 (IL-6) levels and alleviated clinical symptoms in patients with RA. However, in these studies, KD administration was limited to 7 days, reproducing the effects of acute fasting rather than a prolonged weight-loss dietary intervention. Future prospective studies will be needed to elucidate the potential beneficial effects of a KD on specific domains and clinical outcomes in patients with inflammatory arthritis.

Polycystic Ovary Syndrome

Obesity is associated with several endocrine diseases and may itself be a consequence of hormonal disorders, especially in the case of polycystic ovary syndrome (PCOS). Indeed, PCOS is associated with many obesity-related comorbidities, such as insulin resistance (50%–90% incidence), type 2 diabetes, dyslipidemia, nonalcoholic fatty liver disease, hyperinsulinemia, and glucose intolerance. 136 , 137 At present, PCOS cannot be cured, but its symptoms may be managed with medications (eg, metformin) and lifestyle changes. Since a weight loss of as little as 5% can lead to a significant improvement in PCOS, weight-loss interventions constitute a promising approach. A clinical study by Li et al 138 observed that an 8-hour time-limited feeding improved the hormonal and metabolic profiles of patients with PCOS.

Studies by Paoli et al 139 have shown that the KD is also beneficial for overweight women with PCOS, leading to a significant body-weight reduction and lowering blood glucose, insulin levels, and testosterone levels. Li et al 140 showed that a 12-week period on a KD along with conventional pharmaceutical treatment improved the menstrual cycle. However, the question remains as to how the KD should be composed in terms of its lipid constituents. In fact, some studies have shown that the consumption of significant amounts of trans -unsaturated fats by women resulted in a 2-fold greater risk of ovulation disorders. 141 , 142 This emphasizes that the composition of the KD must be adjusted to accommodate the patient’s needs, especially when the regimen is planned over the long term.

Cancer

According to research from the American Cancer Society, excessive body fat may be responsible for approximately 11% of cancers in women and 5% of cancers in men in the United States. 143 Overall, approximately 1 in 20 cancers are associated with obesity. 144 Excess body fat is linked to a higher risk of developing multiple types of cancer, including meningioma, adenocarcinoma of the esophagus, multiple myeloma, kidney, uterus, thyroid, breast, liver, gallbladder, upper stomach, ovarian, pancreatic, colon, and rectal cancers. 145 Standard cancer treatments, such as radiation therapy, chemotherapy, and immunotherapy, have limitations and often have side effects. For this reason, many new strategies for reducing cancer have emerged. Special emphasis is placed on energy management by cancer cells that prefer glucose as their primary energy source. For example, leukemic cells create a diabetes-like state by reducing the availability of glucose to normal cells, leading to greater use of glucose by leukemic cells. 146 This sparked the debate as to whether reducing carbohydrates and replacing them with lipids could be a new window in cancer treatment. Not all of the controversy surrounding some of these issues has yet been resolved. The switch to ketone bodies as an alternative main fuel seems promising, especially by virtue of the anti-inflammatory properties of ketone bodies. Also, there are studies confirming that cancer cells are unable to use ketone bodies due to acquired metabolic inflexibility. Certain tumor types show decreased levels of β-hydroxybutyrate dehydrogenase (BDH1) and succinyl-CoA-3-ketoacid-CoA transferase (SCOT1), and even undetectable acetyl-CoA acetyltransferase 1 (ACAT1). Nevertheless, the ketolytic enzyme expression seems to be cell/tissue-specific. For example, in cervical cancer–derived HeLa cells, BDH1/SCOT1 expression was high, but not in pancreatic cancer PANC-1 cells. 147 Moreover, supplementation with ketone bodies (especially BHB) has proven harmful in cancer cells due to abnormalities in the structure of the mitochondria. 148

Lin et al 149 reported that dietary restriction alone reduces the density of microvessels, leading to an anti-tumor effect in lung and breast cancer. Another study by Allen et al 150 has shown that following a KD increases the sensitivity of A549 lung cancer xenografts to carboplatin and reduces proliferation when combined with radiotherapy. This nutritional pattern has also been reported to be an effective adjuvant therapy in radiotherapy for the treatment of brain tumors. 151 In a case report, a 65-year-old patient with glioblastoma multiforme treated with radiotherapy and chemotherapy and following a KD displayed tumor regression, supporting the potential effectiveness of an adjuvant KD in this type of cancer. 152 In colon cancer, a KD with concomitant omega-3 fatty acid and MCT supplementation resulted in significant tumor growth inhibition. 153 A study performed in women with ovarian or endometrial cancer showed that elevated serum BHB may reflect a metabolic environment inhospitable to cancer proliferation. 154 During the 12-week study duration, the KD did not negatively affect quality of life of the patients and improved patients’ physical function end energy expenditure while diminishing food cravings. Also, the KD had no adverse effects on blood lipids, suggesting that ketone bodies are a safe and achievable component of treatment for some patients with cancer. 155 , 156

On the other hand, some studies have shown the limitations of following a KD in patients with cancer. Porper et al 157 have shown that high levels of nutritional ketosis were not achievable in 13 adults with glioblastoma treated with a KD for 8 weeks. In other studies, this dietary regimen even showed pro-cancer effects or the results were inconclusive. Chu-Shore and Thiele 158 reported that, in 3 out of 5 children of patients with tuberous sclerosis complex, the implementation of a KD resulted in the progression of an existing tumor or the formation of a new tumor. Zahra et al 159 then investigated the possible effects of a KD in patients with locally advanced non–small cell lung cancer and pancreatic cancer. The studies were conducted with simultaneous radiotherapy and chemotherapy. The difficulty of patients to follow a KD under these conditions was noticeable, giving an inconclusive result possibly due to low compliance to the diet. This area of research requires more in-depth investigation with an emphasis on treatment duration and long-term follow-up.

CONCLUSION

The evidence supporting the KD (or ketone body supplementation) in the regulation of metabolism and body weight remains incomplete. While there is research supporting certain benefits, individual responses to ketogenic nutrition can vary, and the long-term effects of a KD are still being studied. Table 4 presents the supportive evidence for the use of a KD, as well as potential drawbacks. 160–169

Overall, the currently available evidence supports the potential for ketogenesis-inducing dietary habits as an aid to induce weight loss and treat obesity-related diseases, at least in a transitory manner, perhaps through reduced appetite and reduced calorie intake. At present, the long-term safety of ketosis in weight-loss interventions remains unknown, and it is of the utmost importance to only switch to ketogenic regimens after appropriate medical consulting.

Acknowledgments

The authors apologize to colleagues whose scientific work has not been cited because of space constraints.

Contributor Information

Marta Biesiekierska, Department of Oncobiology and Epigenetics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland.

Maura Strigini, University Jean Monnet Saint-Etienne, INSERM, Mines Saint Etienne, SAINBIOSE U1059, F-42023 Saint-Etienne, France.

Agnieszka Śliwińska, Department of Nucleic Acid Biochemistry, Medical University of Lodz, 92-213 Lodz, Poland.

Luciano Pirola, INSERM Unit 1060, CarMeN Laboratory, Lyon 1 University, F-69495 Pierre Bénite, France.

Aneta Balcerczyk, Department of Oncobiology and Epigenetics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland.

Author Contributions

Conceptualization: A.B. and L.P.; data collection and data interpretation: all authors; writing—original draft preparation: M.B, M.S., A.Ś., L.P., and A.B.; figures: M.B., L.P., and A.B.; supervision and project administration: A.B.; funding acquisition: A.B., M.S. and L.P. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Polish National Science Centre, Project Grant NCN Harmonia, No. 2018/30/M/NZ3/00682. M.S. was supported by intramural funding from University Jean Monnet (UJM) Saint-Etienne and INSERM, the AAP 2017 of UJM Saint-Etienne, and the French Rheumatology Society (SFR 2020). L.P. and A.B. were supported by the 2021 EFSD-Boehringer Ingelheim funding program.

Conflicts of Interest

None declared.

Data Availability

Not applicable.

REFERENCES

1. Hall KD, Ayuketah A, Brychta R, et al. Ultra-processed diets cause excess calorie intake and weight gain: an inpatient randomized controlled trial of ad libitum food intake. Cell Metab. 2019;30:67-77.e3. 10.1016/j.cmet.2019.05.008

2. Curran F, Davis ME, Murphy K, et al. Correlates of physical activity and sedentary behavior in adults living with overweight and obesity: a systematic review. Obes Rev. 2023;24:e13615. 10.1111/obr.13615

3. Bray GA, Frühbeck G, Ryan DH, Wilding JPH. Management of obesity. Lancet. 2016;387:1947-1956. 10.1016/S0140-6736(16)00271-3

4. Yoong SL, Chai LK, Williams CM, Wiggers J, Finch M, Wolfenden L. Systematic review and meta‐analysis of interventions targeting sleep and their impact on child body mass index, diet, and physical activity. Obesity (Silver Spring). 2016;24:1140-1147. 10.1002/oby.21459

5. van Baak MA, Mariman ECM. Obesity-induced and weight-loss-induced physiological factors affecting weight regain. Nat Rev Endocrinol. 2023;19:655-670. 10.1038/s41574-023-00887-4

6. Jaacks LM, Vandevijvere S, Pan A, et al. The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol. 2019;7:231-240. 10.1016/S2213-8587(19)30026-9

7. Purnell JQ. Definitions, classification, and epidemiology of obesity. In: Feingold KR, Anawalt B, Blackman MR, et al. , eds. Endotext [Internet] . MDText.com, Inc.; 2000.

8. Achamrah N, Colange G, Delay J, et al. Comparison of body composition assessment by DXA and BIA according to the body mass index: a retrospective study on 3655 measures. PLoS One. 2018;13:e0200465. 10.1371/journal.pone.0200465

9. Schnall PL, Dobson M, Landsbergis P. Globalization, work, and cardiovascular disease. Int J Health Serv. 2016;46:656-692. 10.1177/0020731416664687

10. Scherer PE, Hill JA. Obesity, diabetes, and cardiovascular diseases. Circ Res. 2016;118:1703-1705. 10.1161/CIRCRESAHA.116.308999

11. Beak JS, Kim YT, Lee SH. Predisposing factors for posttraumatic osteoarthritis after malleolus fracture fixation in patients younger than 50 years. Foot Ankle Int. 2022;43:389-397. 10.1177/10711007211050039

12. Hazlehurst JM, Singh P, Bhogal G, Broughton S, Tahrani AA. How to manage weight loss in women with obesity and PCOS seeking fertility? Clin Endocrinol (Oxf). 2022;97:208-216. 10.1111/cen.14726

13. Hunter E, Avenell A, Maheshwari A, Stadler G, Best D. The effectiveness of weight‐loss lifestyle interventions for improving fertility in women and men with overweight or obesity and infertility: a systematic review update of evidence from randomized controlled trials. Obes Rev. 2021;22:e13325. 10.1111/obr.13325

14. Adnan Y, Ali SMA, Awan MS, et al. Body mass index and diabetes mellitus may predict poorer overall survival of oral squamous cell carcinoma patients: a retrospective cohort from a tertiary-care centre of a resource-limited country. Clin Med Insights Oncol. 2022;16:11795549221084832. 10.1177/11795549221084832

15. Bou Malhab LJ, Abdel-Rahman WM. Obesity and inflammation: colorectal cancer engines. Curr Mol Pharmacol. 2022;15:620-646. 10.2174/1874467214666210906122054

16. Sakai NS, Taylor SA, Chouhan MD. Obesity, metabolic disease and the pancreas—quantitative imaging of pancreatic fat. Br J Radiol. 2018;91:20180267. 10.1259/bjr.20180267

17. Milaneschi Y, Simmons WK, van Rossum EFC, Penninx BW. Depression and obesity: evidence of shared biological mechanisms. Mol Psychiatry. 2019;24:18-33. 10.1038/s41380-018-0017-5

18. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression. Arch Gen Psychiatry. 2010;67:220-229. 10.1001/archgenpsychiatry.2010.2

19. Mazereel V, Detraux J, Vancampfort D, van Winkel R, De Hert M. Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness. Front Endocrinol (Lausanne). 2020;11:573479. 10.3389/fendo.2020.573479

20. Lennerz BS, Koutnik AP, Azova S, Wolfsdorf JI, Ludwig DS. Carbohydrate restriction for diabetes: rediscovering centuries-old wisdom. J Clin Invest. 2021;131:e142246. 10.1172/JCI142246

21. Cooder HR. Epilepsy in children: with particular reference to the ketogenic diet. Cal West Med. 1933;39:169-173. PMID: 18742621

22. IJff DM, Postulart D, Lambrechts DAJE, et al. Cognitive and behavioral impact of the ketogenic diet in children and adolescents with refractory epilepsy: a randomized controlled trial. Epilepsy Behav. 2016;60:153-157. 10.1016/j.yebeh.2016.04.033

23. Ros Pérez P, Zamarrón Cuesta I, Aparicio Meix M, Sastre Gallego A. Evaluation of the effectiveness of the ketogenic diet with medium-chain triglycerides, in the treatment of refractory epilepsy in children. Apropos of a series of cases. An Esp Pediatr. 1989;30:155-158. PMID: 2729781

24. Sandu C, Burloiu CM, Barca DG, Magureanu SA, Craiu DC. Ketogenic diet in patients with GLUT1 deficiency syndrome. Maedica (Bucur). 2019;14:93-97. 10.26574/maedica.2019.14.2.93

25. Institute of Medicine (US); Subcommittee on Interpretation and Uses of Dietary Reference Intakes; Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. DRI Dietary Reference Intakes: Applications in Dietary Assessment. National Academies Press; 2000. 10.17226/9956

26. Yalcin T, Al A, Rakıcıoğlu N. The effects of meal glycemic load on blood glucose levels of adults with different body mass indexes. Indian J Endocrinol Metab. 2017;21:71-75. 10.4103/2230-8210.195995

27. Wallace CW, Fordahl SC. Obesity and dietary fat influence dopamine neurotransmission: exploring the convergence of metabolic state, physiological stress, and inflammation on dopaminergic control of food intake. Nutr Res Rev. 2022;35:236-251. 10.1017/S0954422421000196

28. Speakman JR, Hall KD. Carbohydrates, insulin, and obesity. Science. 2021;372:577-578. 10.1126/science.aav0448

29. Schugar RC, Crawford PA. Low-carbohydrate ketogenic diets, glucose homeostasis, and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2012;15:374-380. 10.1097/MCO.0b013e3283547157

30. Spriet LL. New insights into the interaction of carbohydrate and fat metabolism during exercise. Sports Med. 2014;44(Suppl 1):S87-S96. 10.1007/s40279-014-0154-1

31. Volek JS, Noakes T, Phinney SD. Rethinking fat as a fuel for endurance exercise. Eur J Sport Sci. 2015;15:13-20. 10.1080/17461391.2014.959564

32. Shah AM, Wondisford FE. Tracking the carbons supplying gluconeogenesis. J Biol Chem. 2020;295:14419-14429. 10.1074/jbc.REV120.012758

33. Lilly LN, Heiss CJ, Maragoudakis SF, Braden KL, Smith SE. The effect of added peanut butter on the glycemic response to a high–glycemic index meal: a pilot study. J Am Coll Nutr. 2019;38:351-357. 10.1080/07315724.2018.1519404

34. De Souza RJ, Mente A, Maroleanu A, et al. Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ. 2015;351:H3978. 10.1136/bmj.h3978

35. Li Y, Hruby A, Bernstein AM, et al. Saturated fats compared with unsaturated fats and sources of carbohydrates in relation to risk of coronary heart disease: a prospective cohort study. J Am Coll Cardiol. 2015;66:1538-1548. 10.1016/j.jacc.2015.07.055

36. Lemeshow AR, Rimm EB, Hasin DS, et al. Food and beverage consumption and food addiction among women in the Nurses’ Health Studies. Appetite. 2018;121:186-197. 10.1016/j.appet.2017.10.038

37. Jaworowska A, Blackham T, Davies IG, Stevenson L. Nutritional challenges and health implications of takeaway and fast food. Nutr Rev. 2013;71:310-318. 10.1111/nure.12031

38. Lovejoy JC, Smith SR, Champagne CM, et al. Effects of diets enriched in saturated (palmitic), monounsaturated (oleic), or trans (elaidic) fatty acids on insulin sensitivity and substrate oxidation in healthy adults. Diabetes Care. 2002;25:1283-1288. 10.2337/diacare.25.8.1283

39. Oteng A-B, Kersten S. Mechanisms of action of trans fatty acids. Adv Nutr. 2020;11:697-708. 10.1093/advances/nmz125

40. Mozaffarian D, Clarke R. Quantitative effects on cardiovascular risk factors and coronary heart disease risk of replacing partially hydrogenated vegetable oils with other fats and oils. Eur J Clin Nutr. 2009;63(Suppl 2):S22-33. 10.1038/sj.ejcn.1602976

41. Zhu XF, Hu YQ, Dai ZC, Li XJ, Zhang J. Associations between trans fatty acids and systemic immune-inflammation index: a cross-sectional study. Lipids Health Dis. 2024;23:122. 10.1186/s12944-024-02109-w

42. Wanders AJ, Brouwer IA, Siebelink E, Katan MB. Effect of a high intake of conjugated linoleic acid on lipoprotein levels in healthy human subjects. PLoS One. 2010;5:e9000. 10.1371/journal.pone.0009000

43. Matthan NR, Lovato L, Petersen KS, et al. Effect of daily avocado consumption for 6 mo compared with habitual diet on red blood cell fatty acid profiles and association with cardiometabolic risk factors in individuals with abdominal obesity: a randomized trial. Am J Clin Nutr. 2024;120:794-803. 10.1016/j.ajcnut.2024.08.002

44. Mann GV. Metabolic consequences of dietary trans fatty acids. Lancet. 1994;343:1268-1271. 10.1016/s0140-6736(94)92157-1

45. Scholz A, Navarrete-Muñoz EM, García-de-la-Hera M, et al. Association between trans fatty acid intake and overweight including obesity in 4 to 5-year-old children from the INMA study. Pediatr Obes. 2019;14:e12528. 10.1111/ijpo.12528

46. Sun L, Goh HJ, Govindharajulu P, Leow MK, Henry CJ. Differential effects of monounsaturated and polyunsaturated fats on satiety and gut hormone responses in healthy subjects. Foods. 2019;8:634. 10.3390/foods8120634

47. Stevenson JL, Paton CM, Cooper JA. Hunger and satiety responses to high-fat meals after a high-polyunsaturated fat diet: a randomized trial. Nutrition. 2017;41:14-23. 10.1016/j.nut.2017.03.008

48. Fukao T, Lopaschuk GD, Mitchell GA. Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry. Prostaglandins Leukot Essent Fatty Acids. 2004;70:243-251. 10.1016/j.plefa.2003.11.001

49. Nelson AB, Queathem ED, Puchalska P, Crawford PA. Metabolic messengers: ketone bodies. Nat Metab. 2023;5:2062-2074. 10.1038/s42255-023-00935-3

50. Dąbek A, Wojtala M, Pirola L, Balcerczyk A. Modulation of cellular biochemistry, epigenetics and metabolomics by ketone bodies. Implications of the ketogenic diet in the physiology of the organism and pathological states. Nutrients. 2020;12:788. 10.3390/nu12030788

51. Huang W, Ramsey KM, Marcheva B, Bass J. Circadian rhythms, sleep, and metabolism. J Clin Invest. 2011;121:2133-2141. 10.1172/JCI46043

52. Owen OE, Felig P, Morgan AP, Wahren J, Cahill GF. Liver and kidney metabolism during prolonged starvation. J Clin Invest. 1969;48:574-583. 10.1172/JCI106016

53. Jensen J, Rustad PI, Kolnes AJ, Lai Y-C. The role of skeletal muscle glycogen breakdown for regulation of insulin sensitivity by exercise. Front Physiol. 2011;2:112. 10.3389/fphys.2011.00112

54. Evans M, Cogan KE, Egan B. Metabolism of ketone bodies during exercise and training: physiological basis for exogenous supplementation. J Physiol. 2017;595:2857-2871. 10.1113/JP273185

55. Mikkelsen KH, Seifert T, Secher NH, Grøndal T, van Hall G. Systemic, cerebral and skeletal muscle ketone body and energy metabolism during acute hyper-D-β-hydroxybutyratemia in post-absorptive healthy males. J Clin Endocrinol Metab. 2015;100:636-643. 10.1210/jc.2014-2608

56. Fery F, Balasse EO. Effect of exercise on the disposal of infused ketone bodies in humans. J Clin Endocrinol Metab. 1988;67:245-250. 10.1210/jcem-67-2-245

57. Balasse EO, Féry F. Ketone body production and disposal: effects of fasting, diabetes, and exercise. Diabetes Metab Rev. 1989;5:247-270. 10.1002/dmr.5610050304

58. Balasse EO, Fery F, Neef MA. Changes induced by exercise in rates of turnover and oxidation of ketone bodies in fasting man. J Appl Physiol Respir Environ Exerc Physiol. 1978;44:5-11. 10.1152/jappl.1978.44.1.5

59. Pedroso JAB, Nishimura LS, de Matos‐Neto EM, Donato J, Tirapegui J. Leucine improves protein nutritional status and regulates hepatic lipid metabolism in calorie‐restricted rats. Cell Biochem Funct. 2014;32:326-332. 10.1002/cbf.3017

60. Harvey CJdC, Schofield GM, Williden M. The use of nutritional supplements to induce ketosis and reduce symptoms associated with keto-induction: a narrative review. PeerJ. 2018;6:e4488. 10.7717/peerj.4488

61. Harvey CJdC, Schofield GM, Williden M, McQuillan JA. The effect of medium chain triglycerides on time to nutritional ketosis and symptoms of keto-induction in healthy adults: a randomised controlled clinical trial. J Nutr Metab. 2018;2018:2630565-2630569. 10.1155/2018/2630565

62. Jensen NJ, Wodschow HZ, Nilsson M, Rungby J. Effects of ketone bodies on brain metabolism and function in neurodegenerative diseases. Int J Mol Sci. 2020;21:8767. 10.3390/ijms21228767

63. Stubbs BJ, Cox PJ, Evans RD, et al. On the metabolism of exogenous ketones in humans. Front Physiol. 2017;8:848. 10.3389/fphys.2017.00848

64. Poff AM, Koutnik AP, Egan B. Nutritional ketosis with ketogenic diets or exogenous ketones: features, convergence, and divergence. Curr Sports Med Rep. 2020;19:251-259. 10.1249/JSR.0000000000000732

65. Soto-Mota A, Vansant H, Evans RD, Clarke K. Safety and tolerability of sustained exogenous ketosis using ketone monoester drinks for 28 days in healthy adults. Regul Toxicol Pharmacol. 2019;109:104506. 10.1016/j.yrtph.2019.104506

66. Walsh JJ, Neudorf H, Little JP. 14-Day ketone supplementation lowers glucose and improves vascular function in obesity: a randomized crossover trial. J Clin Endocrinol Metab. 2021;106:1738-1754. 10.1210/clinem/dgaa925

67. Maalouf M, Rho JM, Mattson MP. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev. 2009;59:293-315. 10.1016/j.brainresrev.2008.09.002

68. Yang MU, Van Itallie TB. Composition of weight lost during short-term weight reduction. Metabolic responses of obese subjects to starvation and low-calorie ketogenic and nonketogenic diets. J Clin Invest. 1976;58:722-730. 10.1172/JCI108519

69. Brouns F. Overweight and diabetes prevention: is a low-carbohydrate–high-fat diet recommendable? Eur J Nutr. 2018;57:1301-1312. 10.1007/s00394-018-1636-y

70. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 2003;348:2082-2090. 10.1056/NEJMoa022207

71. Shai I, Schwarzfuchs D, Henkin Y, et al. ; Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008;359:229-241. 10.1056/NEJMoa0708681

72. Ebbeling CB, Feldman HA, Klein GL, et al. Effects of a low carbohydrate diet on energy expenditure during weight loss maintenance: randomized trial. BMJ. 2018;363: K 4583. 10.1136/bmj.k4583

73. Athinarayanan SJ, Adams RN, Hallberg SJ, et al. Long-term effects of a novel continuous remote care intervention including nutritional ketosis for the management of type 2 diabetes: a 2-year non-randomized clinical trial. Front Endocrinol (Lausanne). 2019;10:348. 10.3389/fendo.2019.00348

74. Lennerz BS, Barton A, Bernstein RK, et al. Management of type 1 diabetes with a very low–carbohydrate diet. Pediatrics. 2018;142:e20181536B. 10.1542/peds.2017-3349

75. Bueno NB, de Melo ISV, de Oliveira SL, da Rocha Ataide T. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. Br J Nutr. 2013;110:1178-1187. 10.1017/S0007114513000548

76. Liu YC. Medium‐chain triglyceride (MCT) ketogenic therapy. Epilepsia. 2008;49(Suppl 8):33-36. 10.1111/j.1528-1167.2008.01830.x

77. Vidić V, Ilić V, Toskić L, Janković N, Ugarković D. Effects of calorie restricted low carbohydrate high fat ketogenic vs. non-ketogenic diet on strength, body-composition, hormonal and lipid profile in trained middle-aged men. Clin Nutr. 2021;40:1495-1502. 10.1016/j.clnu.2021.02.028

78. Kysel P, Haluzíková D, Doležalová RP, et al. The influence of cyclical ketogenic reduction diet vs. nutritionally balanced reduction diet on body composition, strength, and endurance performance in healthy young males: a randomized controlled trial. Nutrients. 2020;12:2832. 10.3390/nu12092832

79. Johnstone AM, Horgan GW, Murison SD, Bremner DM, Lobley GE. Effects of a high-protein ketogenic diet on hunger, appetite, and weight loss in obese men feeding ad libitum. Am J Clin Nutr. 2008;87:44-55. 10.1093/ajcn/87.1.44

80. Zoccali C, Bellizzi V, Minutolo R, Mallamaci F, Conte G, De Nicola L. The effect of a ketogenic diet on weight loss in CKD: a randomized controlled trial in obese stage G1-3a CKD patients. Clin Kidney J. 2023;16:2309-2313. 10.1093/ckj/sfad176

81. Basciani S, Camajani E, Contini S, et al. Very-low-calorie ketogenic diets with whey, vegetable, or animal protein in patients with obesity: a randomized pilot study. J Clin Endocrinol Metab. 2020;105:dgaa336. 10.1210/clinem/dgaa336

82. Molteberg E, Thorsby PM, Kverneland M, et al. Stress biomarkers in adult patients with drug-resistant epilepsy on a modified Atkins diet: a prospective study. Epilepsia Open. 2023;8:1331-1339. 10.1002/epi4.12808

83. Gibson AA, Seimon RV, Lee CMY, et al. Do ketogenic diets really suppress appetite? A systematic review and meta‐analysis. Obes Rev. 2015;16:64-76. 10.1111/obr.12230

84. Hession M, Rolland C, Kulkarni U, Wise A, Broom J. Systematic review of randomized controlled trials of low‐carbohydrate vs. low‐fat/low‐calorie diets in the management of obesity and its comorbidities. Obes Rev. 2009;10:36-50. 10.1111/j.1467-789X.2008.00518.x

85. Foster GD, Wyatt HR, Hill JO, et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet. Ann Intern Med. 2010;153:147-157. 10.7326/0003-4819-153-3-201008030-00005

86. Mohler ER, Sibley AA, Stein R, et al. Endothelial function and weight loss: comparison of low‐carbohydrate and low‐fat diets. Obesity (Silver Spring). 2013;21:504-509. 10.1002/oby.20055

87. Arora N, Pulimamidi S, Yadav H, et al. Intermittent fasting with ketogenic diet: a combination approach for management of chronic diseases. Clin Nutr ESPEN. 2023;54:166-174. 10.1016/j.clnesp.2023.01.024

88. Ganesan K, Habboush Y, Sultan S. Intermittent fasting: the choice for a healthier lifestyle. Cureus. 2018;10:e2947. 10.7759/cureus.2947

89. Harvie M, Howell A. Potential benefits and harms of intermittent energy restriction and intermittent fasting amongst obese, overweight and normal weight subjects—a narrative review of human and animal evidence. Behav Sci. 2017;7:4. 10.3390/bs7010004

90. Harvie MN, Pegington M, Mattson MP, et al. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond). 2011;35:714-727. 10.1038/ijo.2010.171

91. Harvie M, Wright C, Pegington M, et al. The effect of intermittent energy and carbohydrate restriction v. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. Br J Nutr. 2013;110:1534-1547. 10.1017/S0007114513000792

92. Carter S, Clifton PM, Keogh JB. The effect of intermittent compared with continuous energy restriction on glycaemic control in patients with type 2 diabetes: 24-month follow-up of a randomised noninferiority trial. Diabetes Res Clin Pract. 2019;151:11-19. 10.1016/j.diabres.2019.03.022

93. Dong TA, Sandesara PB, Dhindsa DS, et al. Intermittent fasting: a heart healthy dietary pattern? Am J Med. 2020;133:901-907. 10.1016/j.amjmed.2020.03.030

94. Gangitano E, Gnessi L, Lenzi A, Ray D. Chronobiology and metabolism: is ketogenic diet able to influence circadian rhythm? Front Neurosci. 2021;15:756970. 10.3389/fnins.2021.756970

95. Blanco JC, Khatri A, Kifayat A, Cho R, Aronow WS. Starvation ketoacidosis due to the ketogenic diet and prolonged fasting—a possibly dangerous diet trend. Am J Case Rep. 2019;20:1728-1731. 10.12659/AJCR.917226

96. Conklin HW. Cause and treatment of epilepsy. J Am Osteopathic Assoc. 1922;26:11-14.

97. Wheless JW. History of the ketogenic diet. Epilepsia. 2008;49(Suppl 8):3-5. 10.1111/j.1528-1167.2008.01821.x

98. Sampaio LPdB. Ketogenic diet for epilepsy treatment. Arq Neuropsiquiatr. 2016;74:842-848. 10.1590/0004-282X20160116

99. O’Neill B, Raggi P. The ketogenic diet: pros and cons. Atherosclerosis. 2020;292:119-126. 10.1016/j.atherosclerosis.2019.11.021

100. Keith L, Seo CA, Rowsemitt C, et al. Ketogenic diet as a potential intervention for lipedema. Med Hypotheses. 2021;146:110435. 10.1016/j.mehy.2020.110435

101. Tchernof A, Després J-P. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93:359-404. 10.1152/physrev.00033.2011

102. Ballak DB, Stienstra R, Tack CJ, Dinarello CA, van Diepen JA. IL-1 family members in the pathogenesis and treatment of metabolic disease: focus on adipose tissue inflammation and insulin resistance. Cytokine. 2015;75:280-290. 10.1016/j.cyto.2015.05.005

103. Frayn KN, Karpe F, Fielding BA, Macdonald IA, Coppack SW. Integrative physiology of human adipose tissue. Int J Obes Relat Metab Disord. 2003;27:875-888. 10.1038/sj.ijo.0802326

104. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension. Circ Res. 2015;116:991-1006. 10.1161/CIRCRESAHA.116.305697

105. Benjamin EJ, Virani SS, Callaway CW, et al. ; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation. 2018;137:e67-e492. 10.1161/CIR.0000000000000558

106. Shariq OA, McKenzie TJ. Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. Gland Surg. 2020;9:80-93. 10.21037/gs.2019.12.03

107. Murashige D, Jang C, Neinast M, et al. Comprehensive quantification of fuel use by the failing and nonfailing human heart. Science. 2020;370:364-368. 10.1126/science.abc8861

108. Abdul Kadir A, Clarke K, Evans RD. Cardiac ketone body metabolism. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165739. 10.1016/j.bbadis.2020.165739

109. Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2013;304:H1060-76. 10.1152/ajpheart.00646.2012

110. Aubert G, Martin OJ, Horton JL, et al. The failing heart relies on ketone bodies as a fuel. Circulation. 2016;133:698-705. 10.1161/CIRCULATIONAHA.115.017355

111. Yurista SR, Chong C-R, Badimon JJ, Kelly DP, de Boer RA, Westenbrink BD. Therapeutic potential of ketone bodies for patients with cardiovascular disease. J Am Coll Cardiol. 2021;77:1660-1669. 10.1016/j.jacc.2020.12.065

112. Takahara S, Soni S, Maayah ZH, Ferdaoussi M, Dyck JRB. Ketone therapy for heart failure: current evidence for clinical use. Cardiovasc Res. 2022;118:977-987. 10.1093/cvr/cvab068

113. Pirola L, Ciesielski O, Balcerczyk A. Fat not so bad? The role of ketone bodies and ketogenic diet in the treatment of endothelial dysfunction and hypertension. Biochem Pharmacol. 2022;206:115346. 10.1016/j.bcp.2022.115346

114. Tzenios N, Lewis ED, Crowley DC, Chahine M, Evans M. Examining the efficacy of a very-low-carbohydrate ketogenic diet on cardiovascular health in adults with mildly elevated low-density lipoprotein cholesterol in an open-label pilot study. Metab Syndr Relat Disord. 2022;20:94-103. 10.1089/met.2021.0042

115. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88. 10.1186/1471-2458-9-88

116. Cashen K, Petersen T. Diabetic ketoacidosis. Pediatr Rev. 2019;40:412-420. 10.1542/pir.2018-0231

117. Dhatariya KK. Defining and characterising diabetic ketoacidosis in adults. Diabetes Res Clin Pract. 2019;155:107797. 10.1016/j.diabres.2019.107797

118. Tallis J, James RS, Seebacher F. The effects of obesity on skeletal muscle contractile function. J Exp Biol. 2018;221:16384. 10.1242/jeb.163840

119. Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL; IOF Bone and Diabetes Working Group. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13:208-219. 10.1038/nrendo.2016.153

120. Iyer A, Fairlie DP, Prins JB, Hammock BD, Brown L. Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol. 2010;6:71-82. 10.1038/nrendo.2009.264

121. Bliddal H, Leeds AR, Christensen R. Osteoarthritis, obesity and weight loss: evidence, hypotheses and horizons—a scoping review. Obes Rev. 2014;15:578-586. 10.1111/obr.12173

122. King LK, March L, Anandacoomarasamy A. Obesity & osteoarthritis. Indian J Med Res. 2013;138:185-193. PMID: 24056594

123. Zapata-Linares N, Eymard F, Berenbaum F, Houard X. Role of adipose tissues in osteoarthritis. Curr Opin Rheumatol. 2021;33:84-93. 10.1097/BOR.0000000000000763

124. Fan J, Zhu J, Sun L, Li Y, Wang T, Li Y. Causal association of adipokines with osteoarthritis: a Mendelian randomization study. Rheumatology (Oxford). 2021;60:2808-2815. 10.1093/rheumatology/keaa719

125. Wang T, He C. Pro-inflammatory cytokines: the link between obesity and osteoarthritis. Cytokine Growth Factor Rev. 2018;44:38-50. 10.1016/j.cytogfr.2018.10.002

126. Mathus-Vliegen EMH, Basdevant A, Finer N, et al. ; Obesity Management Task Force of the European Association for the Study of Obesity. Prevalence, pathophysiology, health consequences and treatment options of obesity in the elderly: a guideline. Obes Facts. 2012;5:460-483., 10.1159/000341193

127. Babu S, Vaish A, Vaishya R, Agarwal A. Can intermittent fasting be helpful for knee osteoarthritis? J Clin Orthop Trauma. 2021;16:70-74. 10.1016/j.jcot.2020.12.020

128. Muthuri SG, Hui M, Doherty M, Zhang W. What if we prevent obesity? Risk reduction in knee osteoarthritis estimated through a meta-analysis of observational studies. Arthritis Care Res (Hoboken). 2011;63:982-990. 10.1002/acr.20464

129. Drinda S, Franke S, Schmidt S, et al. AGE-RAGE interaction does not explain the clinical improvements after therapeutic fasting in osteoarthritis. Complement Med Res. 2018;25:167-172. 10.1159/000486237

130. Strath LJ, Jones CD, Philip George A, et al. The effect of low-carbohydrate and low-fat diets on pain in individuals with knee osteoarthritis. Pain Med. 2020;21:150-160. 10.1093/pm/pnz022

131. Masino SA, Ruskin DN. Ketogenic diets and pain. J Child Neurol. 2013;28:993-1001. 10.1177/0883073813487595

132. Marques Miranda C, de Lima Campos M, Leite-Almeida H. Diet, body weight and pain susceptibility—a systematic review of preclinical studies. Neurobiol Pain. 2021;10:100066. 10.1016/j.ynpai.2021.100066

133. Felson DT, Misra D, LaValley M, et al. Fatty acids and osteoarthritis: the MOST study. Osteoarthritis Cartilage. 2021;29:973-978. 10.1016/j.joca.2021.03.006

134. Fraser DA, Thoen J, Bondhus S, et al. Reduction in serum leptin and IGF-1 but preserved T-lymphocyte numbers and activation after a ketogenic diet in rheumatoid arthritis patients. Clin Exp Rheumatol. 2000;18:209-214.

135. Fraser DA, Thoen J, Djøseland O, Førre O, Kjeldsen-Kragh J. Serum levels of interleukin-6 and dehydroepiandrosterone sulphate in response to either fasting or a ketogenic diet in rheumatoid arthritis patients. Clin Exp Rheumatol. 2000;18:357-362.

136. Deswal R, Narwal V, Dang A, Pundir C. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13:261-271. 10.4103/jhrs.JHRS_95_18

137. Barber TM, Hanson P, Weickert MO, Franks S. Obesity and polycystic ovary syndrome: implications for pathogenesis and novel management strategies. Clin Med Insights Reprod Health. 2019;13:1179558119874042. 10.1177/1179558119874042

138. Li C, Xing C, Zhang J, Zhao H, Shi W, He B. Eight-hour time-restricted feeding improves endocrine and metabolic profiles in women with anovulatory polycystic ovary syndrome. J Transl Med. 2021;19:148. 10.1186/s12967-021-02817-2

139. Paoli A, Mancin L, Giacona MC, Bianco A, Caprio M. Effects of a ketogenic diet in overweight women with polycystic ovary syndrome. J Transl Med. 2020;18:104. 10.1186/s12967-020-02277-0

140. Li J, Bai W-P, Jiang B, et al. Ketogenic diet in women with polycystic ovary syndrome and liver dysfunction who are obese: a randomized, open‐label, parallel‐group, controlled pilot trial. J Obstet Gynaecol Res. 2021;47:1145-1152. 10.1111/jog.14650

141. Kulak D, Polotsky AJ. Should the ketogenic diet be considered for enhancing fertility? Maturitas. 2013;74:10-13. 10.1016/j.maturitas.2012.10.003

142. Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Dietary fatty acid intakes and the risk of ovulatory infertility. Am J Clin Nutr. 2007;85:231-237. 10.1093/ajcn/85.1.231

143. Accessed November 2024. https://www.cancer.org/cancer/cancer-causes/diet-physical-activity/body-weight-and-cancer-risk/effects.html

144. Accessed November 2024. https://www.worldwidecancerresearch.org/news-opinion/2020/october/what-is-the-link-between-obesity-and-cancer/

145. Accessed November 2024. https://www.cdc.gov/cancer/obesity/index.htm

146. Ye H, Adane B, Khan N, et al. Subversion of systemic glucose metabolism as a mechanism to support the growth of leukemia cells. Cancer Cell. 2018;34:659-673.e6. 10.1016/j.ccell.2018.08.016

147. Zhang J, Jia P-P, Liu Q-L, et al. Low ketolytic enzyme levels in tumors predict ketogenic diet responses in cancer cell lines in vitro and in vivo. J Lipid Res. 2018;59:625-634. 10.1194/jlr.M082040

148. Feng S, Wang H, Liu J, AA J, Zhou F, Wang G. Multi-dimensional roles of ketone bodies in cancer biology: opportunities for cancer therapy. Pharmacol Res. 2019;150:104500. 10.1016/j.phrs.2019.104500

149. Lin B-Q, Zeng Z-Y, Yang S-S, Zhuang C-W. Dietary restriction suppresses tumor growth, reduces angiogenesis, and improves tumor microenvironment in human non-small-cell lung cancer xenografts. Lung Cancer. 2013;79:111-117. 10.1016/j.lungcan.2012.11.001

150. Allen BG, Bhatia SK, Buatti JM, et al. Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. Clin Cancer Res. 2013;19:3905-3913. 10.1158/1078-0432.CCR-12-0287

151. Woolf EC, Syed N, Scheck AC. Tumor metabolism, the ketogenic diet and β-hydroxybutyrate: novel approaches to adjuvant brain tumor therapy. Front Mol Neurosci. 2016;9:122. 10.3389/fnmol.2016.00122

152. Zuccoli G, Marcello N, Pisanello A, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case Rrport. Nutr Metab (Lond). 2010;7:33. 10.1186/1743-7075-7-33

153. Hao G-W, Chen Y-S, He D-M, Wang H-Y, Wu G-H, Zhang B. Growth of human colon cancer cells in nude mice is delayed by ketogenic diet with or without omega-3 fatty acids and medium-chain triglycerides. Asian Pac J Cancer Prev. 2015;16:2061-2068. 10.7314/APJCP.2015.16.5.2061

154. Cohen CW, Fontaine KR, Arend RC, Gower BA. A ketogenic diet is acceptable in women with ovarian and endometrial cancer and has no adverse effects on blood lipids: a randomized, controlled trial. Nutr Cancer. 2020;72:584-594. 10.1080/01635581.2019.1645864

155. Cohen C, Fontaine K, Arend R, Soleymani T, Gower B. Favorable effects of a ketogenic diet on physical function, perceived energy, and food cravings in women with ovarian or endometrial cancer: a randomized, controlled trial. Nutrients. 2018;10:1187. 10.3390/nu10091187

156. Cohen CW, Fontaine KR, Arend RC, et al. A ketogenic diet reduces central obesity and serum insulin in women with ovarian or endometrial cancer. J Nutr. 2018;148:1253-1260. 10.1093/jn/nxy119

157. Porper K, Zach L, Shpatz Y, et al. Dietary-induced ketogenesis: adults are not children. Nutrients. 2021;13:3093. 10.3390/nu13093093

158. Chu-Shore CJ, Thiele EA. Tumor growth in patients with tuberous sclerosis complex on the ketogenic diet. Brain Dev. 2010;32:318-322. 10.1016/j.braindev.2009.04.009

159. Zahra A, Fath MA, Opat E, et al. Consuming a ketogenic diet while receiving radiation and chemotherapy for locally advanced lung cancer and pancreatic cancer: the University of Iowa experience of two phase 1 clinical trials. Radiat Res. 2017;187:743-754. 10.1667/RR14668.1

160. Tragni E, Vigna L, Ruscica M, et al. Reduction of cardio-metabolic risk and body weight through a multiphasic very-low calorie ketogenic diet program in women with overweight/obesity: a study in a real-world setting. Nutrients. 2021;13:1804. 10.3390/nu13061804

161. Arslan N, Guzel O, Kose E, et al. Is ketogenic diet treatment hepatotoxic for children with intractable epilepsy? Seizure. 2016;43:32-38. 10.1016/j.seizure.2016.10.024

162. Vargas-Molina S, García-Sillero M, Bonilla DA, Petro JL, García-Romero J, Benítez-Porres J. The effect of the ketogenic diet on resistance training load management: a repeated-measures clinical trial in trained participants. J Int Soc Sports Nutr. 2024;21:2306308. 10.1080/15502783.2024.2306308

163. Cho W, Jung H, Hong S, et al. The effect of a short-term ketogenic diet on exercise efficiency during graded exercise in healthy adults. J Int Soc Sports Nutr. 2023;20:2264278. 10.1080/15502783.2023.2264278

164. McKay AKA, Pyne DB, Burke LM, Peeling P. Iron metabolism: interactions with energy and carbohydrate availability. Nutrients. 2020;12:3692. 10.3390/nu12123692

165. Li S, Yuan S, Lin G, Zhang J. Effects of a two meals-a-day ketogenic diet on newly diagnosed obese patients with type 2 diabetes mellitus: a retrospective observational study. Medicine (Baltimore). 2023;102: E 35753. 10.1097/MD.0000000000035753

166. Watanabe M, Tuccinardi D, Ernesti I, et al. Scientific evidence underlying contraindications to the ketogenic diet: an update. Obes Rev. 2020;21:E13053. 10.1111/obr.13053

167. Leow ZZX, Guelfi KJ, Davis EA, Jones TW, Fournier PA. The glycaemic benefits of a very‐low‐carbohydrate ketogenic diet in adults with type 1 diabetes mellitus may be opposed by increased hypoglycaemia risk and dyslipidaemia. Diabet Med. 2018;35:1258-1263. 10.1111/dme.13663

168. Graybeal AJ, Kreutzer A, Moss K, Shah M. Changes in the chronic and postprandial blood lipid profiles of trained competitive cyclists and triathletes following a ketogenic diet: a randomized crossover trial. BMC Sports Sci Med Rehabil. 2024;16:19. 10.1186/s13102-023-00801-5

169. Berry-Kravis E, Booth G, Sanchez AC, Woodbury-Kolb J. Carnitine levels and the ketogenic diet. Epilepsia. 2001;42:1445-1451. 10.1046/j.1528-1157.2001.18001.x

Associated Data

Data Availability Statement

Not applicable.